24 research outputs found
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane
Recently, an inverse
relationship between resistance to
platinum-based chemotherapeutic agents and
taxanes has been implicated in breast and
ovarian cancers, and a possible pivotal role for
BRCA1 has also been suggested. Because
cis-diamminedichloroplatinum
(CDDP) and taxanes are the most active antitumor
agents against head and neck squamous cell
carcinoma (HNSCC), we analyzed the sensitivity
of nine HNSCC cell lines and their previously
established derived CDDP-resistant cell lines to
two representative taxanes: docetaxel and
paclitaxel. None of the nine original cell lines
showed any cross resistance between CDDP and
taxanes, but one of the CDDP-resistant cell
lines, RPMI2650CR, demonstrated hypersensitivity
to both taxanes when compared to the parental
cell line, RPMI2650. Furthermore, RPMI2650CR
exhibited increased expression of BRCA1. These
data suggest that (i) taxanes are a good
candidate for a second-line therapeutic drug for
HNSCC patients with acquired CDDP resistance
and (ii) BRCA1 can be a candidate marker for
predicting an inverse CDDP/taxane sensitivity
phenotype in HNSCC
Superselective Drug Delivery Using Doxorubicin-Encapsulated Liposomes and Ultrasound in a Mouse Model of Lung Metastasis Activation
A novel approach to translymphatic chemotherapy targeting sentinel lymph nodes of patients with oral cancer using intra-arterial chemotherapy - preliminary study
Concomitant chemoradiotherapy using docetaxel, cisplatin and 5-FU for the patients with advanced hypopharyngeal cancer: Second report.
Clinical Study of Multiple Primary Cancer in Patients with Oral and Oropharyngeal Cancer
Concomitant chemoradiotherapy using modified TPF (docetaxel, cisplatin and 5-FU) for the patients with advanced sino-nasal squamous cell carcinoma.
Superselective Drug Delivery Using Doxorubicin-Encapsulated Liposomes and Ultrasound in a Mouse Model of Lung Metastasis Activation
The role of initial neck dissection for patients with node-positive oropharyngeal squamous cell carcinomas
Background: The current study sought to assess the role of initial neck dissection (ND) for patients with node-positive oropharyngeal squamous cell carcinomas (OPSCC). Methods: The data for 202 patients with previously untreated node-positive OPSCC were gathered from 12 institutions belonging to the Head and Neck Cancer Study Group in the Japan Clinical Oncology Group. These patients were categorized into two groups, consisting of the initial ND group and the wait-and-see group, according to treatment policy. Results: Regional recurrence was observed in 17 of 93 patients undergoing initial ND, whereas, recurrent or persistent diseases were observed in 40 of 109 patients who did not undergo initial ND. The 4-year overall survival rates (OS) for the wait-and-see group and initial ND groups were 74.0% and 78.7%, respectively, and the 4-year regional control rates (RC) for each group were 77.6% and 84.9%. There were no significant differences in either OS or RC (p = 0.3440 and p = 0.2382, respectively). However, for patients with N3 disease, the 4-year OS of the initial ND group (100%) was favorable. For patients with N2a disease, the 4-year RC of the initial ND group was higher than that of the wait-and-see group statistically (100% vs 62.5%, p = 0.0156). Conclusions: The role of initial ND was limited in patients with node-positive OPSCC. The treatment strategy not involving initial ND is considered feasible and acceptable when nodal evaluation after definitive radiotherapy or chemoradiotherapy is applied adequately. However, it is possible that initial ND improves outcomes in patients with resectable large-volume nodal disease. (C) 2014 Elsevier Ltd. All rights reserved